Mutations of the p53 Gene in Pancreatic Cancer
Author Information
Author(s): C.M. Barton, S.L. Staddon, C.M. Hughes, P.A. Hall, C. O'Sullivan, G. Kloppel, B. Theis, R.C.G. Russell, J. Neoptolemos, R.C.N. Williamson, D.P. Lane, N.R. Lemoine
Primary Institution: Imperial Cancer Research Fund Oncology Group
Hypothesis
The study investigates the prevalence of abnormalities of the p53 protein in human pancreatic cancer.
Conclusion
The study found that p53 activation is an important event in human pancreatic tumorigenesis.
Supporting Evidence
- 60% of frozen pancreatic cancer samples showed immunodetectable p53.
- 23% of paraffin-embedded pancreatic cancer cases were positive for p53.
- Point mutations were found in three of the CM1-positive cases.
Takeaway
This study looked at pancreatic cancer and found that a lot of the cancer cells had problems with a gene called p53, which helps stop tumors from growing.
Methodology
The study used immunohistochemistry and direct sequencing of genomic DNA to examine pancreatic cancer samples.
Limitations
The study was limited by the small sample size and the inability to confirm allelic deletions due to lack of high molecular weight DNA.
Want to read the original?
Access the complete publication on the publisher's website